Drug Trial Radar · NCT00262080
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Dec 31, 2005
Primary completion
Dec 31, 2005
Study completion Feb 28, 2007
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 6, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe acute attacks of HAE.
Conditions
- Hereditary Angioedema (HAE)
Interventions
ecallantideDrug
dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
Phosphate Buffer Saline (PBS),Drug
given as three 1mL subcutaneous injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Outcome Score at 4 Hours Post-DoseTime frame: 4 hours post-dose (DOUBLE-BLIND PART)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute for Asthma and Allergy
Wheaton, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.